169 related articles for article (PubMed ID: 34600258)
1. The impact of COVID-19 on opioid treatment programs in the United States.
Goldsamt LA; Rosenblum A; Appel P; Paris P; Nazia N
Drug Alcohol Depend; 2021 Nov; 228():109049. PubMed ID: 34600258
[TBL] [Abstract][Full Text] [Related]
2. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
3. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
Brothers S; Viera A; Heimer R
J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
[TBL] [Abstract][Full Text] [Related]
4. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs.
Krawczyk N; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Bandara S
J Addict Med; 2022 Nov-Dec 01; 16(6):645-652. PubMed ID: 35165225
[TBL] [Abstract][Full Text] [Related]
5. State guidance and system changes related to COVID-19: Impact on opioid treatment programs.
Fuller DB; Gryczynski J; Schwartz RP; Halsted C; Mitchell SG; Whitter M
J Subst Use Addict Treat; 2024 Mar; 158():209214. PubMed ID: 38042301
[TBL] [Abstract][Full Text] [Related]
6. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
[TBL] [Abstract][Full Text] [Related]
7. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
[TBL] [Abstract][Full Text] [Related]
8. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
[No Abstract] [Full Text] [Related]
9. The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?
Tracy K; Wachtel L; Friedman T
J Subst Abuse Treat; 2021 Dec; 131():108394. PubMed ID: 34098292
[TBL] [Abstract][Full Text] [Related]
10. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
[TBL] [Abstract][Full Text] [Related]
11. Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey.
Saloner B; Krawczyk N; Solomon K; Allen ST; Morris M; Haney K; Sherman SG
Int J Drug Policy; 2022 Mar; 101():103537. PubMed ID: 34871945
[TBL] [Abstract][Full Text] [Related]
12. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
13. Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
Meyerson BE; Bentele KG; Russell DM; Brady BR; Downer M; Garcia RC; Garnett I; Lutz R; Mahoney A; Samorano S; Arredondo C; Andres HJ; Coles H; Granillo B
PLoS One; 2022; 17(10):e0274094. PubMed ID: 36282806
[TBL] [Abstract][Full Text] [Related]
14. "How will I get my next week's script?" Reactions of Reddit opioid forum users to changes in treatment access in the early months of the coronavirus pandemic.
Krawczyk N; Bunting AM; Frank D; Arshonsky J; Gu Y; Friedman SR; Bragg MA
Int J Drug Policy; 2021 Jun; 92():103140. PubMed ID: 33558165
[TBL] [Abstract][Full Text] [Related]
15. Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
Roy V; Buonora M; Simon C; Dooling B; Joudrey P
Int J Drug Policy; 2024 Feb; 124():104302. PubMed ID: 38183861
[TBL] [Abstract][Full Text] [Related]
16. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
17. Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey.
Brothers S; Palayew A; Simon C; Coulter A; Strichartz K; Voyles N; Vincent L
Harm Reduct J; 2023 Mar; 20(1):31. PubMed ID: 36894968
[TBL] [Abstract][Full Text] [Related]
18. Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
Walters SM; Perlman DC; Guarino H; Mateu-Gelabert P; Frank D
Subst Use Misuse; 2022; 57(7):1144-1153. PubMed ID: 35443862
[No Abstract] [Full Text] [Related]
19. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
20. Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms.
Treitler PC; Bowden CF; Lloyd J; Enich M; Nyaku AN; Crystal S
J Subst Abuse Treat; 2022 Jan; 132():108514. PubMed ID: 34098210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
